Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 10, 2011, Pages 912-922

  Stevens, Philip ^a   Foulkes, Rhiannon E ^a   Hartford Beynon, Jake S ^a   Delicata, Raymond J ^a  

^a NEVILL HALL HOSPITAL   (United Kingdom)

Author keywords

digestive system fistula; intestinal fistula; lanreotide; octreotide; somatostatin

Indexed keywords

ANGIOPEPTIN; INSULIN; OCTREOTIDE; SOMATOSTATIN;

ANEMIA; BILE DUCT FISTULA; CHEST INFECTION; COMORBIDITY; DEHYDRATION; DEPRESSION; DIETARY INTAKE; ENTEROCUTANEOUS FISTULA; GASTROINTESTINAL SURGERY; GLUCOSE INTOLERANCE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; LENGTH OF STAY; MALNUTRITION; META ANALYSIS; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL FISTULA; MALE; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052656818     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834a345d     Document Type: Review

References (60)

1. Buchler MW. Gastrointestinal fistulae. Gut 2002; 49 (Suppl IV):iv1. (Pubitemid 33097209)
2. Lloyd DAJ, Gabe SM. Windsor ACJ. Nutrition and management of enterocutaneous fistula. Br J Surg 2006; 93:1045-1055. (Pubitemid 44343500)
3. Berry SM, Fischer JE. Classification and pathophysiology of enterocutaneous fistulas. Surg Clin North Am 1996; 76:1009-1018. (Pubitemid 26315238)
4. Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut 2002; 49 (Suppl IV):iv2-iv10.
5. Sitges-Serra A, Jauretta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery. Br J Surg 1982; 69:147-150. (Pubitemid 12187985)
6. Fagniez PL, Yahchouchy E. Use of somatostatin in the treatment of digestive fistulas. Pharmacoeconomic issues. Digestion 1999; 60 (Suppl 3):65-70. (Pubitemid 29537549)
7. Campos AC, Andrade DF, Campos GM, Matias JE, Coelho JCA. multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg 1999; 188:483-490. (Pubitemid 29214360)
8. Berry SM, Fisher JE. Enterocutaneous fistulas. Curr Probl Surg 1994; 31:469-566.
9. Edmunds LH Jr, Williams GM, Welch CE. External fistulas arising from the gastro-intestinal tract. Ann Surg 1960; 152:445-471.
10. Kuvshinoff BW, Brodish RJ, McFadden DW, Fischer JE. Serum transferrin as a prognostic indicator of spontaneous closure and mortality in gastrointestinal cutaneous fistulas. Ann Surg 1993; 217:615-623. (Pubitemid 23174264)
11. Schwartz RW, Barker DE, Griffen WO Jr, Ross CB, Strodel WE. Gastrointestinal disconnection and the treatment of intra-abdominal sepsis. Am Surg 1989; 55:50-54. (Pubitemid 19051088)
12. Haffejee AA. Surgical management of high output enterocutaneous fistulae: a 24-year experience. Curr Opin Clin Nutr Metab Care 2004; 7:309-316. (Pubitemid 40340669)
13. Raptis S, Schlegel W, Lehmann E, Dollinger HC, Zoupas C. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism 1978; 27:1321-1328. (Pubitemid 9014208)
14. Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol Suppl 1998; 228:115-121. (Pubitemid 28551899)
15. Jost JO, Clemens M, Ruhland D, Bunte H. Somatostatin in pancreas and small intestinal fistulas. Zentralbl Chir 1984; 109:527-531. (Pubitemid 14106966)
16. Mulvihill S, Pappas TN, Passaro E Jr, Debas HT. The use of somatostatin and its analogs in the treatment of surgical disorders. Surgery 1986; 100:467-476. (Pubitemid 16054071)
17. Gorden P, Comi RJ, Maton PN, Go VLNIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110:35-50. (Pubitemid 19032792)
18. Lambert SWJ, Van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246-254. (Pubitemid 26030676)
19. Bornschein J, Drozdov I, Malfertheiner P, Octreotide LAR. Safety and tolerability issues. Expert Opin Drug Saf 2009; 8:755-768.
20. Pederzoli P, Bassi C, Falconi M. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin. Surg Gynecol Obstet 1986; 163:428-432. (Pubitemid 17178434)
21. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979; 48:50-53. (Pubitemid 9101608)
22. Bauer W, Briner U, Doepfner W, Haller R, Huquenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133-1140. (Pubitemid 13243115)
23. Kohler E, Beglinger C, Dettwiler S, Whitehouse I, Gyr K. Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1986; 1:154-159. (Pubitemid 17019915)
24. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl 1986; 119:65-72. (Pubitemid 16057845)
25. Miller GV, Preston SR, Woodhouse LF, Farmery SM, Primrose JN. Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues. Gut 1993; 34:1351-1356. (Pubitemid 23293618)
26. Beglinger C, Drewe J. Somatostatin and octreotide: physiological background and pharmacological application. Digestion 1999; 60 (Suppl 2):2-8. (Pubitemid 29178655)
27. Gouillat C, Gigot JF. Pancreatic surgical complications, the case for prophylaxis. Gut 2002; 49 (Suppl IV):iv32-iv39.
28. Gonzalez-Pinto I, Gonzalez EM. Optimising the treatment of upper gastrointestinal fistulae. Gut 2002; 49 (Suppl IV):iv21-iv28.
29. Londong W, Angerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96:713-722. (Pubitemid 19057592)
30. Friess H, Bordhin K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, et al. Inhibition of pancreatic secretion under long-term octreotide treatment in humans. Digestion 1994; 55 (Suppl 1):10-15. (Pubitemid 24020272)
31. Jenkins SA, Nott DM, Baxter JN. Fluctuations in the secretion of pancreatic enzymes between consecutive doses of octreotide: implications for the management of fistulae. Eur J Gastroenterol Hepatol 1995; 7:255-258.
32. Lamberts SWJ, Hofland LJ, Van Koetsveld PM, Reubi JC, Bruining HA, Bakker WH, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumours: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 1990; 71:566-574.
33. Hesse U, Ysebaert D, de Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 2002; 49 (Suppl IV):iv11-iv20.
34. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993; 76:721-727. (Pubitemid 23086495)
35. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994; 130:229-234. (Pubitemid 24117901)
36. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009; 94:654-661.
37. Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis. Can J Surg 2007; 50:459-466.
38. Koti RS, Gurusamy KS, Fusai G, Davidson BR. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford) 2010; 12:155-165.
39. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001; 88:190-199. (Pubitemid 32142703)
40. Martineau P, Shwed JA, Denis R. Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure? Am J Surg 1996; 172:386-395. (Pubitemid 26346958)
41. Furlan AD, Pennick V, Bombardier C, van Tulder MEditorial Board, Cochrane Back Review Group. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009; 34:1929-1941.
42. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations. Br Med J 2004; 328:1490.
43. di Costanzo J, Cano N, Martin J, Richieri JP, Mercier R, Lafille C, et al. Treatment of external gastrointestinal fistulas by a combination of total parenteral nutrition and somatostatin. JPEN J Parenter Enteral Nutr 1987; 11:465-470. (Pubitemid 18015435)
44. Torres AJ, Landa JI, Arguello JM, Silecchia G, Hernandez-Merlo F, Jover JM, et al. Somatostatin in the management of gastrointestinal fistulas. Arch Surg 1992; 127:97-100.
45. Isenmann R, Schielke DJ, Morl FK, Wunsch N, Vestweber KH, Doertenbach JH, et al. Adjuvant therapy with somatostatin iv in postoperative fistulae of the pancreas, gall bladder and small intestine. A multicentre randomised study. Aktuelle Chirurgie 1994; 29:96-99. (Pubitemid 24193097)
46. Nubiola-Calonge P, Badia JM, Sancho J, Gil MJ, Segura M, Sitges-Serra A. Blind evaluation of the effect of Octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet 1987; 2:672-674.
47. Scott NA, Finnegan S, Irving MH. Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study. Acta Gastroenterol Belg 1993; 56:266-270. (Pubitemid 23348850)
48. Sancho JJ, Di Costanzo J, Nubiola P, Larrad A, Beguiristain A, Roqueta F, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients withpostoperative enterocutaneous fistula. Br J Surg 1995; 82:638-641.
49. Hernandez-Aranda JC, Gallo-Chico B, Flores-Ramirez LA, Avalos-Huante R, Mago-Vazquez FJ, Ramirez-Barba EJ. Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition [Spanish]. Nutr Hosp 1996; 11:226-229. (Pubitemid 27394408)
50. Jamil M, Ahmed U, Sobia H. Role of somatostatin analogues in the management of enterocutaneous fistulae. J Coll Physicians Surg Pak 2004; 14:237-240. (Pubitemid 39585655)
51. Leandros E, Antonakis PT, Albanopoulos K, Dervenis C, Konstadoulakis MM. Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Can J Gastroenterol 2004; 18:303-306. (Pubitemid 38801784)
52. Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, et al. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg 2009; 250:872-877.
53. Sancho J, di Costanzo J, Nubiola P, Larrad A, Beguiristain A, Roqueta F, et al. Randomized double-blind and prospective study of the early administration of octreotide and parenteral nutrition in the treatment of postoperative enterocutaneous fistula. Estudio prospectivo, aleatorizado y doble ciego de la administracion precoz de octreotida y nutricion parenteral en el tratamiento de las fistulas enterocutaneas postoperatorias. [Spanish]. Cirugia Espanola 1994; 56 (Suppl 1):38.
54. Roeyen G, Chapelle T, de Bosscher H, Mattheeussen E, Wouters C, Ruppert M, et al. Addition of somatostatin-14 to a standard Total Parenteral Nutrition-mixture in the treatment of fistulae: A clinical, double-blind, randomised, cross-over study. Acta Gastroenterol Belg 2008; 71: 246-249. (Pubitemid 351976349)
55. Mawdsely JM, Hollington P, Bassett P, Windsor AJ, Forbes A, Gabe SM. An analysis of predictive factors for healing and mortality in patients with enterocutaneous fistulas. Aliment Pharmacol Ther 2009; 28: 1111-1121.
56. Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas. Hepatogastroenterology 2002; 49:1010-1012. (Pubitemid 34809774)
57. Gerardo PD, Bernardo AM. Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201-995). [Spanish]. G E N 1994; 48: 209-218.
58. Xeropotamos N, Nastos D, Nousias KH, Christodoulou D, Tsianos EV, Kappas AM. Octreotide plus total parenteral nutrition in patients with external digestive tract fistulas-an evaluation of our experience. Ann Gastroenterol 2005; 18:427-433. (Pubitemid 47381964)
59. Borison DI, Bloom AD, Pritchard TJ. Treatment of enterocutaneous and colocutaneous fistulas with early surgery or somatostatin analog. Dis Colon Rectum 1992; 35:635-639.
60. Alvarez C, McFadden MD, Reber HA. Complicated enterocutaneous fistulas: Failure of octreotide to improve healing. World J Surg 2000; 24:533-538. (Pubitemid 30210841)